Home » NEUROCRINE HITS NEW 52-WEEK LOW
NEUROCRINE HITS NEW 52-WEEK LOW
Shares of Neurocrine Biosciences Inc. sank to a new 52-week low Monday after one analyst said the stock was overpriced despite being off more than 75 percent so far this year. Neurocrine shares fell $1.11, or 7.3 percent, to $14.05 in morning trading on the Nasdaq, and reached a new 52-week low of $13.75 earlier in the session.
The
Houston Chronicle
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May